Daniel Soland - Uniqure NV CEO
| QURE Stock | USD 4.69 0.01 0.21% |
CEO
Daniel Soland is CEO of Uniqure NV
| Age | 60 |
| Address | Paasheuvelweg 25, Amsterdam, Netherlands, 1105 BP |
| Phone | 31 20 240 6000 |
| Web | https://www.uniqure.com |
Uniqure NV Management Efficiency
The company has return on total asset (ROA) of (0.2172) % which means that it has lost $0.2172 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9024) %, meaning that it created substantial loss on money invested by shareholders. Uniqure NV's management efficiency ratios could be used to measure how well Uniqure NV manages its routine affairs as well as how well it operates its assets and liabilities. As of May 4, 2024, Return On Tangible Assets is expected to decline to -0.43. In addition to that, Return On Capital Employed is expected to decline to -0.39. At present, Uniqure NV's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 684.4 M, whereas Non Currrent Assets Other are forecasted to decline to about 3.1 M.Similar Executives
| Showing other executives | CEO Age | ||
| Sarah Boyce | Avidity BiosciencesInc | 52 | |
| William Newell | Sutro Biopharma | 60 | |
| Ilan Ganot | Solid Biosciences LLC | 50 | |
| Arlene Morris | Syndax Pharmaceuticals | 63 | |
| Keith Gottesdiener | Rhythm Pharmaceuticals | 64 | |
| Paula Ragan | X4 Pharmaceuticals | 54 | |
| Terrie Curran | Phathom Pharmaceuticals | 55 | |
| Gaurav Shah | Rocket Pharmaceuticals | 43 | |
| Alexandria Forbes | MeiraGTx Holdings PLC | 59 | |
| Amy MBA | Terns Pharmaceuticals | 53 | |
| Daniel MBA | Acumen Pharmaceuticals | 53 | |
| Alexander Cumbo | Solid Biosciences LLC | 53 | |
| Carole MD | Larimar Therapeutics | 65 | |
| Kenneth Mills | Regenxbio | 49 | |
| Jeremy MBA | Day One Biopharmaceuticals | 53 | |
| Raymond Stevens | Structure Therapeutics American | 60 | |
| Briggs Morrison | Syndax Pharmaceuticals | 56 | |
| David Southwell | Rocket Pharmaceuticals | 57 | |
| Robert Coffin | Replimune Group | 59 | |
| Ton Logtenberg | Merus BV | N/A | |
| Dinesh Patel | Protagonist Therapeutics | 67 | |
Management Performance
| Return On Equity | -0.9 | ||||
| Return On Asset | -0.22 |
Uniqure NV Leadership Team
Elected by the shareholders, the Uniqure NV's board of directors comprises two types of representatives: Uniqure NV inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Uniqure. The board's role is to monitor Uniqure NV's management team and ensure that shareholders' interests are well served. Uniqure NV's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Uniqure NV's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Maria Cantor, Chief Officer | ||
| Carla Poulson, Interim Officer | ||
| Alexander Kuta, Ex Affairs | ||
| Ricardo Dolmetsch, Pres RD | ||
| Pierre Caloz, Chief Officer | ||
| Amin Abujoub, Chief Officer | ||
| Daniel Soland, CEO | ||
| Pr Katus, Chairman UniQureGermany | ||
| Matthew Kapusta, CEO Director | ||
| MBA Tugal, Business Director | ||
| Erin Boyer, Chief Office | ||
| Richard Porter, Chief Officer | ||
| Walid MD, Chief Officer | ||
| Christian Klemt, Principal CFO | ||
| Jeannette JD, Chief Officer | ||
| David Cerveny, Gen Officer |
Uniqure Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Uniqure NV a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.9 | ||||
| Return On Asset | -0.22 | ||||
| Operating Margin | (9.16) % | ||||
| Current Valuation | 139.12 M | ||||
| Shares Outstanding | 48.49 M | ||||
| Shares Owned By Insiders | 9.88 % | ||||
| Shares Owned By Institutions | 82.14 % | ||||
| Number Of Shares Shorted | 2.51 M | ||||
| Price To Earning | 2.51 X | ||||
| Price To Book | 1.10 X |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Uniqure NV using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Uniqure NV. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Uniqure Stock refer to our How to Trade Uniqure Stock guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Uniqure Stock analysis
When running Uniqure NV's price analysis, check to measure Uniqure NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Uniqure NV is operating at the current time. Most of Uniqure NV's value examination focuses on studying past and present price action to predict the probability of Uniqure NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Uniqure NV's price. Additionally, you may evaluate how the addition of Uniqure NV to your portfolios can decrease your overall portfolio volatility.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |
Is Uniqure NV's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Uniqure NV. If investors know Uniqure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Uniqure NV listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.18) | Earnings Share (6.47) | Revenue Per Share 0.332 | Quarterly Revenue Growth (0.94) | Return On Assets (0.22) |
The market value of Uniqure NV is measured differently than its book value, which is the value of Uniqure that is recorded on the company's balance sheet. Investors also form their own opinion of Uniqure NV's value that differs from its market value or its book value, called intrinsic value, which is Uniqure NV's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Uniqure NV's market value can be influenced by many factors that don't directly affect Uniqure NV's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Uniqure NV's value and its price as these two are different measures arrived at by different means. Investors typically determine if Uniqure NV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Uniqure NV's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.